ATE318146T1 - Verfahren zur aufkonzentrierung von antikörperlösungen - Google Patents

Verfahren zur aufkonzentrierung von antikörperlösungen

Info

Publication number
ATE318146T1
ATE318146T1 AT97923962T AT97923962T ATE318146T1 AT E318146 T1 ATE318146 T1 AT E318146T1 AT 97923962 T AT97923962 T AT 97923962T AT 97923962 T AT97923962 T AT 97923962T AT E318146 T1 ATE318146 T1 AT E318146T1
Authority
AT
Austria
Prior art keywords
antibodies solutions
concentrating
concentrating antibodies
solutions
antibodies
Prior art date
Application number
AT97923962T
Other languages
English (en)
Inventor
Julian Marcus Relton
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10794316&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE318146(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE318146T1 publication Critical patent/ATE318146T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT97923962T 1996-05-24 1997-05-22 Verfahren zur aufkonzentrierung von antikörperlösungen ATE318146T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9610992.1A GB9610992D0 (en) 1996-05-24 1996-05-24 Concentrated antibody preparation

Publications (1)

Publication Number Publication Date
ATE318146T1 true ATE318146T1 (de) 2006-03-15

Family

ID=10794316

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97923962T ATE318146T1 (de) 1996-05-24 1997-05-22 Verfahren zur aufkonzentrierung von antikörperlösungen

Country Status (28)

Country Link
US (1) US6252055B1 (de)
EP (1) EP0907378B1 (de)
JP (1) JP3338060B2 (de)
KR (1) KR20000015935A (de)
CN (1) CN1219882A (de)
AP (1) AP9801392A0 (de)
AR (1) AR007249A1 (de)
AT (1) ATE318146T1 (de)
AU (1) AU731950B2 (de)
BR (1) BR9709267A (de)
CA (1) CA2254983A1 (de)
CO (1) CO4850562A1 (de)
CZ (1) CZ382498A3 (de)
DE (1) DE69735295T2 (de)
EA (1) EA001860B1 (de)
ES (1) ES2258277T3 (de)
GB (1) GB9610992D0 (de)
ID (1) ID16966A (de)
IL (1) IL126940A0 (de)
IS (1) IS4892A (de)
NO (1) NO985464L (de)
NZ (1) NZ332625A (de)
PE (1) PE69098A1 (de)
PL (1) PL330111A1 (de)
TR (1) TR199802423T2 (de)
WO (1) WO1997045140A1 (de)
YU (1) YU53098A (de)
ZA (1) ZA974486B (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP1174148A4 (de) * 1999-04-28 2005-05-04 Yamanouchi Pharma Co Ltd Parenterale medizinische zusammensetzungen enthaltend fragmente humanisierter monoklonaler antikörper und methode zur stabilisierung derselben
JP4812228B2 (ja) * 2000-08-10 2011-11-09 中外製薬株式会社 抗体含有溶液の凝集物生成または白濁抑制方法
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
ES2332402T5 (es) * 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US6365395B1 (en) * 2000-11-03 2002-04-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
AU2006202688B2 (en) * 2001-05-31 2009-01-22 Genentech, Inc. Stable liquid formulations of antibodies
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2868614A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
AU2002342151B2 (en) * 2001-10-26 2007-07-19 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
JP5290489B2 (ja) * 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
WO2003066669A2 (en) * 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
EP2311489A3 (de) 2002-02-14 2013-08-21 Chugai Seiyaku Kabushiki Kaisha Formularierung Antikörper-enthaltender Lösungen die einen Zucker als Stabilisator beinhalten.
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EP1551875A4 (de) * 2002-06-21 2006-06-28 Biogen Idec Inc Gepufferte formulierungen zur konzentrierung von antikörpern und verfahren zu deren anwendung
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP3777880A1 (de) 2003-02-10 2021-02-17 Biogen MA Inc. Immunglobulinformulierung und verfahren zur herstellung davon
AU2012202845B2 (en) * 2003-02-10 2014-09-04 Biogen Ma Inc. Immunoglobulin formulation and method of preparation thereof
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
EP1532983A1 (de) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulinpräparationen mit erhöhter Stabilität
CN1953768B (zh) * 2004-02-12 2010-10-13 默克专利有限公司 抗-egfr抗体的高浓缩液体制剂
WO2005086698A2 (en) * 2004-03-04 2005-09-22 Mayo Foundation For Medical Education And Research Methods for altering t cell diversity
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
JP2007537288A (ja) 2004-05-12 2007-12-20 バクスター インターナショナル インコーポレイテッド オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用
JP5634009B2 (ja) 2004-05-12 2014-12-03 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ タンパク質を含み、そして高濃度のタンパク質で注射性能を示すミクロスフェア
MXPA06012990A (es) 2004-05-12 2007-02-12 Baxter Int Microesferas de acidos nucleicos, produccion y suministro de las mismas.
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP1871806A2 (de) 2005-03-08 2008-01-02 Pharmacia & Upjohn Company LLC Antikörperzusammensetzungen gegen madcam
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
AU2006296399B2 (en) * 2005-09-30 2011-01-20 Medimmune Limited Interleukin-13 antibody composition
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
KR20140071452A (ko) 2006-04-05 2014-06-11 애브비 바이오테크놀로지 리미티드 항체 정제
EP2647712A3 (de) 2006-08-04 2013-11-20 Baxter International Inc Zusammensetzung auf Mikrokügelchenbasis zur Vorbeugung und/oder Umkehrung einer Neuerkrankung an autoimmun bedingter Diabetes
EP2527364A1 (de) 2007-03-29 2012-11-28 Abbott Laboratories Kristalline Antikörper gegen menschliches IL-12
WO2008131129A2 (en) 2007-04-17 2008-10-30 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
EP2173163A4 (de) * 2007-07-06 2010-12-08 Glaxosmithkline Llc Antikörperformulierungen
WO2009010269A1 (en) * 2007-07-17 2009-01-22 F.Hoffmann-La Roche Ag Variable tangential flow filtration
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2009068282A1 (en) * 2007-11-29 2009-06-04 F. Hoffmann-La Roche Ag Immunoglobulin aggregates
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2009083225A2 (en) * 2007-12-28 2009-07-09 Biolnvent International Ab Formulation
ES2406029T3 (es) 2008-04-15 2013-06-05 Grifols Therapeutics Inc. Ultrafiltración/diafiltración en dos fases
AU2010221156A1 (en) * 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
US9586180B2 (en) * 2009-03-24 2017-03-07 Wyeth Llc Membrane evaporation for generating highly concentrated protein therapeutics
JP2012526121A (ja) * 2009-05-04 2012-10-25 アボツト・バイオテクノロジー・リミテツド ヒト抗ｔｎｆアルファ抗体の安定した高蛋白質濃度製剤
KR101912169B1 (ko) 2010-02-04 2018-10-26 체에스엘 베링 아게 면역글로불린 제제
EP2361636A1 (de) 2010-02-26 2011-08-31 CSL Behring AG Immunglobulinpräparat und Aufbewahrungssystem für ein Immunglobulinpräparat
CA2976671C (en) 2010-03-01 2021-01-12 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CN103282042B (zh) 2010-09-17 2014-12-10 巴克斯特国际公司 通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白
TWI606840B (zh) 2010-11-11 2017-12-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗-ＴＮＦα抗體之液體調配物
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2013023362A1 (zh) * 2011-08-16 2013-02-21 深圳市卫武光明生物制品有限公司 静注巨细胞病毒人免疫球蛋白及其制备方法
MY165164A (en) 2011-08-26 2018-02-28 Baxalta Inc Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
JP6463268B2 (ja) 2012-09-07 2019-01-30 コヒラス・バイオサイエンシズ・インコーポレイテッド 安定水性アダリムマブ製剤
EP2727602A1 (de) * 2012-10-31 2014-05-07 Takeda GmbH Verfahren zur Herstellung einer hochkonzentrierten Flüssigkeitsformulierung eines Antikörpers
EP2727643A1 (de) 2012-10-31 2014-05-07 Takeda GmbH Ultrafiltrierung von pharmazeutischen Zusammensetzungen
CA2923859C (en) 2013-09-11 2021-11-23 Arsia Therapeutics, Inc. Liquid protein formulations containing viscosity-lowering agents
JP2014062100A (ja) * 2013-11-05 2014-04-10 Glaxosmithkline Llc 抗体処方
EA201692002A1 (ru) * 2014-04-07 2017-01-30 Сиэтл Дженетикс, Инк. Стабильные составы для антител к cd19 и конъюгатов антитело-лекарственное средство
US10400019B2 (en) * 2014-05-01 2019-09-03 Virginia Tech Intellectual Properties, Inc. Keratin nanomaterials and methods of production
SG10201902915VA (en) 2014-10-01 2019-04-29 Eagle Biologics Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
EP3334747B1 (de) 2015-08-13 2023-09-27 Amgen Inc. Geladene tiefenfiltration von antigenbindenden proteinen
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
EA201990998A1 (ru) 2016-10-21 2019-11-29 Фармацевтические составы и способы их получения
EP3606964A4 (de) 2017-04-03 2020-12-09 Immunomedics, Inc. Subkutane verabreichung von antikörper-arzneimittelkonjugaten zur krebstherapie
EP3624846A1 (de) 2017-05-16 2020-03-25 Bhami's Research Laboratory, Pvt. Ltd. Hochkonzentrierte proteinformulierungen mit reduzierter viskosität
US20210171573A1 (en) * 2018-08-14 2021-06-10 Bristol-Myers Squibb Company Improved protein recovery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3272680D1 (en) 1981-05-01 1986-09-25 Miles Lab Oral pharmaceutical composition containing immune globulin
JPH01268646A (ja) * 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
CH684164A5 (de) 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.
DE4211169C1 (de) * 1992-03-31 1993-06-03 Klaus Kretzschmar
WO1993023556A1 (en) * 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
JPH08508240A (ja) 1993-01-12 1996-09-03 ジョージ グリスティーナ，アンソニー 受動免疫の直接的濃厚伝達のための方法および組成物
DE4344824C1 (de) * 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
CN102416176A (zh) * 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂

Also Published As

Publication number Publication date
EA001860B1 (ru) 2001-10-22
ES2258277T3 (es) 2006-08-16
YU53098A (sh) 2000-03-21
KR20000015935A (ko) 2000-03-15
BR9709267A (pt) 1999-08-10
PE69098A1 (es) 1998-12-02
CO4850562A1 (es) 1999-10-26
TR199802423T2 (xx) 1999-02-22
EP0907378A1 (de) 1999-04-14
ZA974486B (en) 1998-11-23
IS4892A (is) 1998-11-10
IL126940A0 (en) 1999-09-22
DE69735295D1 (de) 2006-04-27
DE69735295T2 (de) 2006-10-05
AU731950B2 (en) 2001-04-05
WO1997045140A1 (en) 1997-12-04
AU2958997A (en) 1998-01-05
AP9801392A0 (en) 1998-12-31
CZ382498A3 (cs) 1999-05-12
PL330111A1 (en) 1999-04-26
GB9610992D0 (en) 1996-07-31
JPH11512753A (ja) 1999-11-02
CA2254983A1 (en) 1997-12-04
AR007249A1 (es) 1999-10-27
NO985464L (no) 1999-01-18
NZ332625A (en) 2000-04-28
JP3338060B2 (ja) 2002-10-28
US6252055B1 (en) 2001-06-26
CN1219882A (zh) 1999-06-16
ID16966A (id) 1997-11-27
EA199800946A1 (ru) 1999-06-24
NO985464D0 (no) 1998-11-23
EP0907378B1 (de) 2006-02-22

Similar Documents

Publication Publication Date Title
ATE318146T1 (de) Verfahren zur aufkonzentrierung von antikörperlösungen
DE69824845D1 (de) Verfahren zur aufkonzentration von kohlenwasserstoffen
DE69709061D1 (de) Verfahren zur umsetzung von ethylbenzol
DE69603255D1 (de) Verfahren zur modifizierung von oberflächen
DE69910557D1 (de) Verfahren zur reinigung von aminonitrilen
DE69812693D1 (de) Verfahren zur oligomerisierung von isobuten
DE69535022D1 (de) Verfahren zur verbesserung von destillat
DE69507617D1 (de) Verfahren zur stabilisierung von aufschlämmungen
DE69624729D1 (de) Verfahren zur selektiven öffnung von naphtalinringen
DE69725000D1 (de) Verfahren zur druckformung von gegenständen
DE69518550D1 (de) Verfahren zur bereitung von kohlenwasserstoffe
DE69727395D1 (de) Verfahren zur olefinisomerisierung
DE69715424D1 (de) Verfahren zur halogenierung von isoolefin-para-alkylstyrol-copolymeren
DE69432859D1 (de) Verfahren zur reinigung von kollagenase
DE69630686D1 (de) Verfahren zur echtheitsprüfung von münzen
DE69715234D1 (de) Verfahren zur reinigung von 1,1-difluorethan
DE69534886D1 (de) Verfahren zur Isolierung von Zellkomponenten
DE69715884D1 (de) Verfahren zur reinigung von lactamen
ATA124894A (de) Verfahren zur direktreduktion von eisenoxidhältigem material
DE69723574D1 (de) Verfahren zur detektion von mutationen
DE69711068D1 (de) Verfahren zur kristallisation von losartan
DE69605902D1 (de) Verfahren zur stabilisierung von schlamm
ATE220558T1 (de) Verbessertes verfahren zur stabilisierung von proteinen
DE59706449D1 (de) Verfahren zur aufkonzentrierung von gebrauchten schwefelsäuren
DE69605794D1 (de) Verfahren zur hydrierung von iminen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties